To date, three targeted immunotherapies have been fully approved by the United States Food and Drug Administration (FDA) for the treatment of HNSCC: cetuximab, an anti-EGFR monoclonal antibody; pembrolizumab; and nivolumab, which are ICIs [165]. Here, EGFR is linked to head and neck squamous cell carcinoma.